Capital Fund Management (CFM)
PACB icon

Capital Fund Management (CFM)’s Pacific Biosciences PACB Stock Holding History

Capital Fund Management (CFM)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-172,900
Closed -$237K – 2110
2024
Q2 		$237K Sell
172,900
-168,100
-49% -$339K ﹤0.01% 1832
2024
Q1 		$1.28M Buy
341,000
+78,100
+30% +$457K ﹤0.01% 1626
2023
Q4 		$2.58M Buy
262,900
+192,300
+272% +$1.57M 0.01% 1404
2023
Q3 		$590K Buy
70,600
+21,700
+44% +$248K ﹤0.01% 1766
2023
Q2 		$650K Buy
48,900
+7,900
+19% +$96K ﹤0.01% 1518
2023
Q1 		$475K Buy
+41,000
New +$408K ﹤0.01% 1448
2022
Q1 		– Sell
-15,900
Closed -$325K – 1706
2021
Q4 		$325K Sell
15,900
-22,100
-58% -$533K ﹤0.01% 1517
2021
Q3 		$971K Sell
38,000
-10,800
-22% -$320K 0.01% 1195
2021
Q2 		$1.71M Buy
48,800
+4,600
+10% +$134K 0.01% 998
2021
Q1 		$1.47M Buy
+44,200
New +$1.55M 0.02% 854

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Capital Fund Management (CFM)'s PACB Position: Q4 2022 in Review

Capital Fund Management (CFM) sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 83,468 shares — an estimated $485K sold.

Capital Fund Management (CFM) first reported a position in PACB in Q2 2014 and held it in 3 quarters. The position peaked at $526K in Q2 2016. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

  • Capital Fund Management (CFM) reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 83,468 Pacific Biosciences shares in Q4 2022, an estimated $485K.
  • Capital Fund Management (CFM) first reported a position in Pacific Biosciences in Q2 2014 and held it in 3 quarters.
  • Capital Fund Management (CFM)'s Pacific Biosciences position peaked at $526K in Q2 2016.
  • 236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Capital Fund Management (CFM)'s 13F filing for Q4 2022, filed 13 Feb 2023.